Business & Regulation

The FDA has approved just three biosimilars in 2021 – but the approvals could shake up the field as discussions around interchangeability intensify.

Setting its sights on self-amplifying RNA, AstraZeneca has signed a deal with Imperial College London spinoff VaxEquity.

Sai Rangarao has worked for some of the biggest names in pharma. Here’s his advice to digital marketers in the field.

After nine months of speculation about who will be the next FDA commissioner, we may finally be close to a decision.

We speak with the authors of two studies into extreme increases in US drug pricing, and attempts by lawmakers to bring the price-jackers into line.

We get the lowdown on the Reputation Index, which was recently published by the Association of the British Pharmaceutical Industry.

The pharma industry is one of the biggest targets for cybercrime. How can companies avoid succumbing to attack?

Sitting Down With… Evelina Vågesjö, Chief Executive Officer at Ilya Pharma, Sweden.

On the 70th anniversary of death Henrietta Lacks, we examine her contributions to science and what they mean for modern research.

Mike Rea of IDEA Pharma shares his thoughts on what players in pharma positioning are getting right – and wrong.